M. H. Moehler Et Al. , "Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)," Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology , vol.38, San-Francisco, Costa Rica, 2020
Moehler, M. H. Et Al. 2020. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC). Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology , (San-Francisco, Costa Rica).
Moehler, M. H., Dvorkin, M., Ozguroglu, M., Ryu, M., Muntean, A. S., Lonardi, S., ... Nechaeva, M.(2020). Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC) . Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica
Moehler, Markus Et Al. "Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)," Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 2020
Moehler, Markus H. Et Al. "Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)." Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology , San-Francisco, Costa Rica, 2020
Moehler, M. H. Et Al. (2020) . "Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)." Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Markus H. Moehler Et Al. }, title={Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)}, congress name={Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology}, city={San-Francisco}, country={Costa Rica}, year={2020}}